1. Molecular Properties of WHO Essential Drugs and Provisional Biopharmaceutical Classification
2. Biopharmaceutic and pharmacokinetic aspects of variable bioavailability of rifampicin
3. R. Laing, B. Fourie, G. Ellard, M. Sesay, S. Spinaci, B. Blomberg, D. Bryant, Fixed-dose Combination Tablets for the Treatment of Tuberculosis. Report of an Informal Meeting held in Geneva, Tuesday, 27 April 1999, World Health Organization, Geneva, WHO/CDS/CPC/TB/99, p. 267.
4. B. Blomerg, P. Evans, S. Phanouvong, P. Nunn, Informal Consultation on 4-drug Fixed Dose Combinations (4FDCs) Compliant with the WHO Model List of Essential Drugs, 25–27 August 2001, World Health Organization, Geneva, WHO/CDS/CPC/TB/2002, p. 299.